BRPI1013999A2 - composto de azabiciclo e seu sal. - Google Patents

composto de azabiciclo e seu sal.

Info

Publication number
BRPI1013999A2
BRPI1013999A2 BRPI1013999A BRPI1013999A BRPI1013999A2 BR PI1013999 A2 BRPI1013999 A2 BR PI1013999A2 BR PI1013999 A BRPI1013999 A BR PI1013999A BR PI1013999 A BRPI1013999 A BR PI1013999A BR PI1013999 A2 BRPI1013999 A2 BR PI1013999A2
Authority
BR
Brazil
Prior art keywords
salt
azabicyclic compound
azabicyclic
compound
Prior art date
Application number
BRPI1013999A
Other languages
English (en)
Inventor
Chihoko Yoshimura
Hiromi Oshiumi
Makoto Kitade
Satoshi Yamashita
Suichi Ohkubo
Takao Uno
Yuichi Kawai
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of BRPI1013999A2 publication Critical patent/BRPI1013999A2/pt
Publication of BRPI1013999B1 publication Critical patent/BRPI1013999B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1013999-0A 2009-07-10 2010-07-09 Composto de azabiciclo e um sal deste, produto farmacêutico e composição farmacêutica compreendendo dito composto e uso do mesmo para tratar câncer BRPI1013999B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009-164196 2009-07-10
JP2009164196 2009-07-10
PCT/JP2010/004466 WO2011004610A1 (ja) 2009-07-10 2010-07-09 アザ二環式化合物又はその塩

Publications (2)

Publication Number Publication Date
BRPI1013999A2 true BRPI1013999A2 (pt) 2016-04-05
BRPI1013999B1 BRPI1013999B1 (pt) 2020-06-02

Family

ID=43429037

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013999-0A BRPI1013999B1 (pt) 2009-07-10 2010-07-09 Composto de azabiciclo e um sal deste, produto farmacêutico e composição farmacêutica compreendendo dito composto e uso do mesmo para tratar câncer

Country Status (18)

Country Link
US (2) US8779142B2 (pt)
EP (1) EP2452940B1 (pt)
JP (1) JP5227456B2 (pt)
KR (1) KR101609412B1 (pt)
CN (2) CN102471335B (pt)
AU (1) AU2010269674B2 (pt)
BR (1) BRPI1013999B1 (pt)
CA (1) CA2767556C (pt)
DK (1) DK2452940T3 (pt)
ES (1) ES2527222T3 (pt)
MX (1) MX2012000487A (pt)
MY (1) MY152972A (pt)
PL (1) PL2452940T3 (pt)
PT (1) PT2452940E (pt)
RU (1) RU2565078C2 (pt)
SG (1) SG177306A1 (pt)
TW (1) TWI460177B (pt)
WO (1) WO2011004610A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103140490A (zh) * 2010-07-15 2013-06-05 百时美施贵宝公司 氮杂吲唑化合物
US9266880B2 (en) 2010-11-12 2016-02-23 Bristol-Myers Squibb Company Substituted azaindazole compounds
TW201309672A (zh) * 2011-01-07 2013-03-01 Taiho Pharmaceutical Co Ltd 新穎吲哚、吲唑衍生物或其鹽
BR112013017520A2 (pt) * 2011-01-07 2016-09-27 Taiho Pharmaceutical Co Ltd composto bicíclico ou sal do mesmo
US8969586B2 (en) 2011-09-27 2015-03-03 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
BR112014029674A2 (pt) 2012-06-27 2017-06-27 Hoffmann La Roche composto, composição farmacêutica, método para o tratamento de uma doença, utilização de um composto, conjunto para o tratamento de uma condição mediada pela quinase pim e invenção
EP3037424B1 (en) 2013-08-22 2017-11-08 Taiho Pharmaceutical Co., Ltd. Novel quinoline-substituted compound
HUE053617T2 (hu) 2013-09-30 2021-07-28 Taiho Pharmaceutical Co Ltd Kombinációs rákterápia azabiciklo vegyületet felhasználva
CN105793421A (zh) * 2013-10-02 2016-07-20 大鹏药品工业株式会社 耐性突变型90kDa热休克蛋白质
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
JP6537601B2 (ja) * 2015-05-12 2019-07-03 大鵬薬品工業株式会社 アザ二環式化合物の結晶
IL266239B2 (en) 2016-10-31 2023-10-01 Taiho Pharmaceutical Co Ltd A selective inhibitor of EGFR with an EXON 20 insertion mutation
CN108976150B (zh) * 2017-06-05 2022-11-18 重庆博腾制药科技股份有限公司 一种3-乙基-4-氟苯腈的制备方法
ES3040843T3 (en) 2017-06-30 2025-11-05 Taiho Pharmaceutical Co Ltd Chemotherapy for cancer using azabicyclo compound
HUE066587T2 (hu) 2017-09-01 2024-08-28 Taiho Pharmaceutical Co Ltd Exon-18- és/vagy exon-21-mutáns EGFR-szelektív inhibitor
MA50254A (fr) 2017-09-15 2020-07-22 Taiho Pharmaceutical Co Ltd Agent prophylactique et/ou thérapeutique pour des maladies impliquant l'expression de l'ido
WO2019220512A1 (ja) 2018-05-14 2019-11-21 大鵬薬品工業株式会社 アザ二環式化合物による悪性腫瘍の治療法
WO2020206608A1 (en) 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
BR112022015723A2 (pt) * 2020-02-11 2023-02-14 Syngenta Crop Protection Ag Compostos de amina cíclica pesticidamente ativos
KR20230088763A (ko) * 2020-10-14 2023-06-20 라녹 테라퓨틱스 (항저우) 컴퍼니, 리미티드 표적 단백질 분해를 위한 방법 및 조성물
CN114685492A (zh) * 2020-12-31 2022-07-01 杭州领业医药科技有限公司 Tas-116的晶型及其制备方法、药物组合物和用途
CN116981669B (zh) * 2021-02-05 2024-08-30 上海齐鲁制药研究中心有限公司 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途
CN117003754B (zh) * 2022-04-28 2025-07-25 腾讯科技(深圳)有限公司 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
EP4538257A1 (en) 2022-06-10 2025-04-16 Taiho Pharmaceutical Co., Ltd. Analogues of azabicyclic compounds
JPWO2023238929A1 (pt) 2022-06-10 2023-12-14
CN115960100B (zh) * 2022-12-28 2023-08-18 北京康立生医药技术开发有限公司 一种治疗胃肠道间质瘤药物皮咪特昔布的合成方法
AU2024328480A1 (en) 2023-08-24 2026-04-09 Taiho Pharmaceutical Co., Ltd. Cancer combination therapy using aza bicyclic compound and antiandrogen agent

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451566A (en) * 1993-11-17 1995-09-19 Zeneca Limited Herbicidal pyrrolopyridine compounds
KR20060070572A (ko) * 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Hsp90-저해제로서의 신규 헤테로시클릭 화합물
US20070111995A1 (en) * 2003-12-19 2007-05-17 Allen David G Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
GB0425035D0 (en) * 2004-11-12 2004-12-15 Novartis Ag Organic compounds
DE602006014540D1 (en) * 2005-05-16 2010-07-08 Irm Llc Pyrrolopyridinderivate als proteinkinaseinhibitoren
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Hsp90活性を調節するピラゾール化合物
EP1924557A2 (en) 2005-09-16 2008-05-28 Serenex, Inc. Carbazole derivatives
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
GB0617161D0 (en) 2006-08-31 2006-10-11 Vernalis R&D Ltd Enzyme inhibitors
JP5401329B2 (ja) * 2007-03-20 2014-01-29 キュリス,インコーポレイテッド Hsp90インヒビターとしての縮合アミノピリジン
AU2008232354B9 (en) * 2007-03-27 2012-07-26 Synta Pharmaceuticals Corp. Triazinone and diazinone derivatives useful as Hsp90 inhibitors
KR20110128942A (ko) 2009-03-19 2011-11-30 사노피 Hsp90 억제 인다졸 유도체, 그를 함유하는 조성물 및 그의 용도
TW201309672A (zh) 2011-01-07 2013-03-01 Taiho Pharmaceutical Co Ltd 新穎吲哚、吲唑衍生物或其鹽
BR112013017520A2 (pt) 2011-01-07 2016-09-27 Taiho Pharmaceutical Co Ltd composto bicíclico ou sal do mesmo

Also Published As

Publication number Publication date
PT2452940E (pt) 2015-02-27
AU2010269674A1 (en) 2012-01-19
KR101609412B1 (ko) 2016-04-05
CA2767556A1 (en) 2011-01-13
DK2452940T3 (en) 2015-01-12
BRPI1013999B1 (pt) 2020-06-02
MY152972A (en) 2014-12-15
JP5227456B2 (ja) 2013-07-03
US20120108589A1 (en) 2012-05-03
EP2452940A1 (en) 2012-05-16
RU2565078C2 (ru) 2015-10-20
JPWO2011004610A1 (ja) 2012-12-20
WO2011004610A1 (ja) 2011-01-13
US8779142B2 (en) 2014-07-15
AU2010269674A2 (en) 2012-02-16
CN104710420A (zh) 2015-06-17
EP2452940A4 (en) 2012-12-12
RU2012104700A (ru) 2013-08-20
MX2012000487A (es) 2012-01-27
US20140303162A1 (en) 2014-10-09
KR20120035181A (ko) 2012-04-13
HK1164869A1 (en) 2012-09-28
US9273045B2 (en) 2016-03-01
TW201105670A (en) 2011-02-16
CN102471335B (zh) 2015-09-30
CN104710420B (zh) 2016-07-27
SG177306A1 (en) 2012-02-28
CA2767556C (en) 2017-11-28
EP2452940B1 (en) 2014-12-17
TWI460177B (zh) 2014-11-11
PL2452940T3 (pl) 2015-05-29
CN102471335A (zh) 2012-05-23
AU2010269674B2 (en) 2014-01-16
ES2527222T3 (es) 2015-01-21

Similar Documents

Publication Publication Date Title
BRPI1013999A2 (pt) composto de azabiciclo e seu sal.
BRPI1016150A2 (pt) compostos heterocíclicos e seus usos.
PT2496533T (pt) Ligantes para materiais de construção
BRPI1009415A2 (pt) escova de dentes.
CO6970589A2 (es) Ansolvatos de sal de noribogaina
BRPI1015203A2 (pt) agentes antimicrobianos
BRPI1014369A2 (pt) sal de abt-263 e suas formas em estado sólido
BR112012013651A2 (pt) sistema de gerenciamento de empreendimento
BRPI0816278A2 (pt) forma sal
BR112013018517A2 (pt) sistema de trinco
BRPI1010217A2 (pt) sistema
BRPI0911679A2 (pt) composto aciltiouréia, ou sal do mesmo, e seu uso
BRPI0807004A2 (pt) Sal
BR112012000281A2 (pt) proteína quimérica.
BRPI1011460A2 (pt) Composição desinfetante.
BR112014001265A2 (pt) composto de amidina ou seu sal
BRPI1006691A2 (pt) sistema
BRPI1014417A2 (pt) sistema
BRPI1006968A2 (pt) microbiocidas
ES2617187T8 (es) Derivados de sal de benzoquinolizinio como agentes anticancerosos
BR112012010510A2 (pt) trator
BRPI1007883A2 (pt) sal, e, cristal.
BR112012003347A2 (pt) sistema
FR2943937B1 (fr) Tondeuse corporelle aspirante
BRPI1006688A2 (pt) sistema

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/07/2010, OBSERVADAS AS CONDICOES LEGAIS.